AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03687086 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Program B
Description: Cognitive behavioral therapy type B plus medications in packaging type B.
Study NCT03046459 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNZ132-1-40
Description: pegylated peptide inhibiting IL-2, IL-9 and IL-15
Study NCT01738581 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-specific Therapy
Description: A non-specific massage and stretching program directed to the hand, wrist and forearm
Study NCT01623661 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: hypertonic saline
Description: hypertonic saline 3.0 % (7 ml/kg)
Study NCT01614665 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Participants receive an initial total daily dose of tacrolimus depending on the type of organ transplant (heart = 0.075 mg/kg; liver/kidney = 0.3 mg/kg), to be given orally (or via nasogastric tube for liver transplant recipients) in 2 doses in the morning and the evening. The first dose is administered in the morning within days of skin closure (heart = 4 days; liver = 2 days; kidney = within 24 hours following reperfusion). Subsequent tacrolimus doses are taken orally twice a day in the morning and evening and are adjusted on the basis of clinical evidence of efficacy, occurrence of adverse events and observing the recommended whole blood trough level ranges (day 1 through 21 = 10 to 20 ng/mL; day 22 through 365 = 5 to 15 ng/mL).
Study NCT01614665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus prolonged release
Description: Participants receive an initial total daily dose of tacrolimus prolonged release depending on the type of organ transplant (heart = 0.075 mg/kg; liver/kidney = 0.3 mg/kg), to be given orally (or via nasogastric tube for liver transplant recipients) in 1 dose. The first dose is administered in the morning within days of skin closure (heart = 4 days; liver = 2 days; kidney = within 24 hours following reperfusion). Subsequent tacrolimus prolonged release doses are taken orally once a day in the morning and are adjusted on the basis of clinical evidence of efficacy, occurrence of adverse events and observing the recommended whole blood trough level ranges (day 1 through 21 = 10 to 20 ng/mL; day 22 through 365 = 5 to 15 ng/mL).
Study NCT05001100 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rehabilitation
Description: rehabilitation
Study NCT05001100 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: rehabilitation
Description: rehabilitation
Study NCT02218567 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: questionnaire qualilty of life
Study NCT02218567 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: psychological interview
Study NCT02218567 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: psychological tests
Study NCT02218567 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Motor evaluation
Study NCT02218567 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavioral evaluation
Study NCT02218567 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: cognitive tests
Study NCT04183764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAX-40279-01
Description: Part 1: Dose escalation, MAX-40279-01 twice daily with dose modifications based on tolerability criteria.~Part 2: Dose expansion, Recommended doses from Part 1.
Study NCT01696422 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dengue 1,2,3,4 (attenuated) vaccine
Description: Dose 1000 PFU per virus (1,2,3,4) Route:subcutaneous
Study NCT01696422 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TetraVax-DV Vaccine - Admixture TV003
Description: Dose 1000 PFU per virus (1,2,3,4) Route: subcutaneous
Study NCT01696422 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Route:subcutaneous
Study NCT03556462 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep Health Education
Description: Parents and children receive sleep health education
Study NCT01726868 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Liposorber LA-15 System
Description: Six sessions of blood purification treatment with Liposorber LA-15 System.
Study NCT01867151 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gluten Free Diet
Study NCT01867151 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Normal Diet
Study NCT04788758 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive G8 screening tool administration training
Study NCT04788758 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Screening Questionnaire Administration
Description: Complete G8 screening tool
Study NCT04788758 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Referral
Description: Receive referral
Study NCT04788758 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02336334 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positioning measurement
Description: Logging of posturing informations
Study NCT02336334 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patient feedback
Description: Evaluation of patients questionary
Study NCT02336334 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Usefulness of a sketch
Description: Helping the patients to understand posturing positions by randomized allocation of sketches
Study NCT02336334 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closure rate of macular holes
Description: closure rates of macular holes in the group with macular holes. Measurement using SD-OCT (spectral domain optical coherence tomography=
Study NCT02895087 — intervention group
Intervention type: OTHER
Intervention: Diurnal Variation Group
Description: This intervention occurs over one 24-hour period. Eligible participants will be required to be admitted into a supervised environment for 24-hours arriving no later than 0730. Blood draws will then be taken every 4 hours (0800, 1200, 1600, 2000, 2400 and 0400). Care will be taken to ensure the total blood draws (including the screening visit) stay within Red Cross Guidelines (less than 500 ml every 8 weeks).
Study NCT02895087 — intervention group
Intervention type: OTHER
Intervention: External Stress Group
Description: 2 visits will be required, each lasting approximately 2.5 hours in the afternoon.~At both visits participants will rest quietly for 15 minutes, then have 3 blood draws and 4 saliva samples over approximately one hour. Participants will also be required to complete short questionnaires about their mood and experience.~At the second visit, participants will also complete some thinking and talking tasks. In addition the autonomic nervous system of the participant's will be monitored throughout the visit.
Study NCT01435538 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care pathway.
Description: The intervention group will implement a care pathway for PFF or COPD containing three active components: a formative evaluation of the actual teams' performance, a set of evidence based key interventions and a training in pathway-development.
Study NCT00729833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-751,871
Description: CP-751,871 IV, every 3 weeks
Study NCT00729833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Sunitinib - daily dosing
Study NCT00417079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabazitaxel (XRP6258) (RPR116258)
Description: 25 mg/m\^2 administered by intravenous (IV) route over 1 hour on day 1 of each 21-day cycle
Study NCT00417079 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mitoxantrone
Description: 12 mg/m\^2 administered by intravenous (IV) route over 15-30 minutes on day 1 of each 21-day cycle
Study NCT00417079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 10 mg daily administered by oral route
Study NCT00417079 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: 10 mg daily administered by oral route
Study NCT01383733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5458640
Description: Multiple ascending doses intravenously, weekly or every 2 weeks or every 3 weeks
Study NCT01163097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palifermin
Description: 40 µg/kg IV bolus injections for three consecutive days
Study NCT01163097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Description: Heparin continuous IV infusion
Study NCT00999375 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Study NCT00999375 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Study NCT00999375 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem Solving
Study NCT00999375 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Learning
Study NCT00999375 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior Modification
Study NCT04403698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alendronate Effervescent Oral Tablet
Description: At the earliest three months but no later than four months after the last denosumab injection, subjects will be randomized to effervescent alendronate administered for either 24 or 48 weeks
Study NCT01047839 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IC51
Description: 0.25 ml, 2 i.m. vaccinations at Day 0 and 28
Study NCT01047839 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IC51
Description: 0.5 ml, 2 i.m. vaccinations at Day 0 and 28
Study NCT04370873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-5475
Description: MK-5475 32 µg, 100 µg, 195 µg, 360 µg or 380 µg administered as dry powder inhalation according to randomization. Following review of pharmacokinetic (PK) and safety data, a second 7 days of dosing may be initiated. A dose of up to 360 μg up to twice a day may be administered based on PK data. Dosage may be adjusted downwards in Part 2, if indicated by PK results in Part 1.
Study NCT04370873 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered as dry powder inhalation according to randomization
Study NCT00792948 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic stem cell transplant
Study NCT00459433 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsychosocial intervention
Description: Psychosocial versus usual care
Study NCT00459433 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsychosocial intervention
Description: Psychosocial versus usual care
Study NCT00577096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin Alfa
Description: Epoetin alfa was administered per an IRB approved algorithm to study participants when hemoglobin levels dropped during high dose chemotherapy. The usual dose is 150 units/kg og body weight, three times per week, or 40,000 units weekly, with suggested target hemoglobin range of 10-12 g/dl.
Study NCT00577096 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: A home-based individualized exercise program that incorporated aerobic and strength resistance training.
Study NCT00577096 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Peripheral Blood Stem Cell Transplantation
Description: Standard PBSCT for multiple myeloma
Study NCT00577096 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Red Blood Cell Transfusion
Description: RBC Transfusion was administered as needed
Study NCT00577096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Fifty percent of the participants received 400 mg daily
Study NCT00577096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin, Low-Molecular-Weight
Description: Patients who received thalidomide also received prophylactic low molecular weight heparin
Study NCT00577096 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet Transfusion
Description: Platelet transfusions were administered as needed
Study NCT00577096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Administered with autologous peripheralblood stem cell transplantation (PBSCT) for multiple myeloma
Study NCT00577096 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin Alfa
Description: Epoetin alfa was administered per an IRB approved algorithm to study participants when hemoglobin levels dropped during high dose chemotherapy. The usual dose is 150 units/kg of body weight, three times per week, or 40,000 units weekly, with suggested target hemoglobin range of 10-12 g/dl
Study NCT00577096 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Total Therapy II
Description: Standard Induction chemotherapy care included: vincristine, doxorubicin, and dexamethasone (VAD) (0.5 mg, 10 mg/m2, and 40 mg, respectively);dexamethasone, cyclophosphamide,etoposide, and cisplatin (DCEP) (40 mg, 400 mg/m2, 40 mg/m2, and 15 mg/m2,respectively); and cyclophosphamide,doxorubicin, and dexamethasone (CAD) (750 mg/m2, 15 mg/m2, and 40 mg, respectively) for mobilization.
Study NCT00577096 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Red Blood Cell Transfusion
Description: RBC Transfusion was administered as needed
Study NCT00577096 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thalidomide
Description: Fifty percent of participants received 400 mg daily
Study NCT00577096 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin, Low-Molecular-Weight
Description: Patients who received thalidomide also received prophylactic low molecular weight heparin
Study NCT00577096 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Platelet Transfusion
Description: Platelet transfusions were administered as needed
Study NCT00577096 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan
Description: Administered with autologous peripheralblood stem cell transplantation (PBSCT) for multiple myeloma
Study NCT02973945 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Flow Nasal Cannula
Description: During the pulmonary rehabilitation program, patients will train the aerobic capacity on a treadmill. Patients in the intervention arm will receive oxygen trough High Flow Nasal Cannula (HFNC) at 50 lpm and 40% of oxygen.~The aerobic capacity training plan will be conducted three times a week over 24 sessions.
Study NCT02973945 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The Venturi Mask
Description: During the pulmonary rehabilitation program, patients will train the aerobic capacity on a treadmill. Patients in the control arm will receive oxygen trough The Venturi Mask (VM) at 40% of oxygen.~The aerobic capacity training plan will be conducted three times a week over 24 sessions.
Study NCT02815618 — intervention group
Intervention type: DEVICE
Intervention: BabyLux Neuro-monitor
Description: Measurement of cerebral blood flow index (CBFi) and tissue oxygen saturation (StO2).
Study NCT01995149 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight loss and dietary intervention
Description: The weight loss intervention had a total duration of 6 months. Each participant's caloric prescription represented a deficit of 600 kcal per day as calculated from the person's resting energy expenditure and activity level using the Harris-Benedict equation. In general, prescribed energy intake was between 1200 kcal and 1600 kcal/day. Dietary composition consisted on 50-55% of carbohydrates, 15-20% of protein and 30% of fat and included a wide variety of foods typical of a Mediterranean diet. Patients were also provided with recipes and shopping counselling to improve intervention compliance and to achieve the weight loss goal. Individual consultations with a nutritionist were performed twice a month to motivate the weight loss and reinforce the intervention.
Study NCT00792948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT00792948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IT
Study NCT00792948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Given PO
Study NCT00792948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given IV or PO
Study NCT00792948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study NCT00792948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT00792948 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC
Study NCT00792948 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00792948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV
Study NCT00792948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV or IT
Study NCT00792948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Given IV
Study NCT00792948 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo allogeneic stem cell transplant
Study NCT00792948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO
Study NCT00792948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Given PO
Study NCT00792948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV
Study NCT00792948 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI
Study NCT00792948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study NCT01662882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: florbetapir (18F)
Description: IV injection, 370 MBq(10mCi), single dose
Study NCT01775904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2886721 in a Capsule
Description: Administered orally.
Study NCT01775904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2886721 in an orally disintegrating tablet (ODT)
Description: Administered orally.
Study NCT04838899 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SABR)
Description: SABR to oligoprogressive metastases while continuing abiraterone therapy
Study NCT03106818 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacain with magnesium sulphate
Description: will receive bupivacain 0.125% and magnesium sulphate 5% infusion in the presternum , for 48 hours
Study NCT03106818 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine only
Description: will receive bupivacain 0.125% infusion in the presternum , for 48 hours
Study NCT03106818 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conventional
Description: only conventional post operative analgesics will be used
Study NCT02160587 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloraprep
Description: ChloraPrep will be compared to ZuraPrep with regard to skin sensitization and irritation.
Study NCT02160587 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% Physiological Saline
Description: 0.9% Physiological Saline will be compared to ZuraPrep with regard to skin sensitization and irritation.
Study NCT02160587 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ZuraPrep without IPA
Description: ZuraPrep without IPA will be compared to ZuraPrep with regard to skin sensitization and irritation
Study NCT04010994 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Transorbital electrical stimulation
Description: Transorbital ACS using 8-12 Hz with 0,5-1,5 mA Intensity, during the first two weeks 1/day, after 2/week for 10 weeks, as a home treatment
Study NCT04560257 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow nasal cannula HFNC
Description: High flow nasal cannula HFNC is a device that delivered the warmed and humid air on high flow rate through nose. It is used to treat severe respiratory distress in COVID-19 patients, a non-invasive ventilatory approach which is relative comfortable by using humidified and pre-heated air containing large concentration of oxygen.
Study NCT00374673 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation
Description: Repetitive transcranial magnetic stimulation of the motor cortex (10 Hz) every day during 5 days then every week for 3 weeks then every two weeks for 2 months then every month for 3 additional months
Study NCT00374673 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation
Description: Repetitive transcranial magnetic stimulation of the motor cortex (10 Hz) every day during 5 days then every week for 3 weeks then every two weeks for 2 months then every month for 3 additional months